Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

benzinga.com/analyst-stock-ratings/analyst-color/25/06/46149812/altimmunes-fatty-liver-candidate-faces-differentiation-doubts

On Thursday, Altimmune, Inc. (NASDAQ:ALT) released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
MASH is a severe liver disease characterized by fat buildup and inflammation in the liver, which can lead to…

This story appeared on benzinga.com, 2025-06-27 18:39:38.
The Entire Business World on a Single Page. Free to Use →